Data published in ASCO 2019 showed that the anti-Pd-1 antibody nivolumab combined with the anti-CTLA -4 antibody ipilimumab induced complete pathological remission within 6 weeks in 29% of patients with resectable HCC (43). The gene discussed is RPL17; the disease is hepatocellular carcinoma.